Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S et al.
N Engl J Med 2025; 393: 2395-2408.
Of the 250 patients (among 761) that tested ctDNA-positive and were randomized, median overall survival (hazard ratio for death: 0.59, 95 per cent confidence interval 0.39 to 0.90, P=0.01) and disease-free survival (0.64, 0.47 to 0.87, P=0.005) were improved with atezolizumab. Adverse event rates were similar between groups.
Comment: ctDNA-guided adjuvant treatment delivers survival benefit; precision oncology in action.
.png)
.jpg){kind=logo}
